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Ligand-biased signallingThe calcium sensing receptor (CaSR) is a class C G-protein-coupled receptor that is crucial for the feedback
regulation of extracellular free ionised calcium homeostasis. While extracellular calcium (Ca2+o) is considered
the primary physiological ligand, the CaSR is activated physiologically by a plethora of molecules including
polyamines and L-amino acids. Activation of the CaSR by different ligands has the ability to stabilise unique con-
formations of the receptor, which may lead to preferential coupling of different G proteins; a phenomenon
termed ‘ligand-biased signalling’. While mutations of the CaSR are currently not linked with any malignancies,
altered CaSR expression and function are associated with cancer progression. Interestingly, the CaSR appears to
act both as a tumour suppressor and an oncogene, depending on the pathophysiology involved. Reduced
expression of the CaSR occurs in both parathyroid and colon cancers, leading to loss of the growth suppressing
effect of high Ca2+o. On the other hand, activation of the CaSR might facilitate metastasis to bone in breast and
prostate cancer. A deeper understanding of the mechanisms driving CaSR signalling in different tissues, aided by
a systems biology approach, will be instrumental in developing novel drugs that target the CaSR or its ligands in
cancer. This article is part of a Special Issue entitled: 12th European Symposium on Calcium.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The calcium ion (Ca2+) is crucial for the control of many impor-
tant cellular functions such as proliferation, differentiation, and ﬂuid
secretion. Many organisms express cell-surface sensors for extracellu-
lar Ca2+ (Ca2+o). Ca2+o is the primary physiological ligand of a GF, basic ﬁbroblast growth fac-
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l rights reserved.protein-coupled receptor (GPCR), called the calcium sensing receptor
(CaSR). The receptor is expressed primarily within the chief cells of
the parathyroid glands where, when activated by an excess of
Ca2+o, it decreases the release of the calcium-retaining hormone,
parathyroid hormone (PTH) [1] to maintain Ca2+o within the physio-
logical range (1.1–1.3 mM). Vice versa, in the case of hypocalcemia,
the CaSR is inactive and PTH is released, an event which restores
normocalcemia by acting on the kidneys, to enhance renal Ca2+
reabsorption; the intestine to, increase intestinal Ca2+ absorption
and bone, to mobilise skeletal Ca2+ [1]. A large number of studies
have shown that the CaSR is expressed in many other tissues in the
body, which do not play an obvious role in Ca2+o homeostasis, such
as the breast, blood vessels, liver, and placenta [1]. Altered CaSR ex-
pression and/or activity is associated not only with disorders of the
parathyroid glands, but also with other conditions like osteoporosis,
vascular calciﬁcation and cancer.
The CaSR is involved in the regulation of a number of diverse pro-
cesses, such as hormone secretion, gene expression, ion channel ac-
tivity, modulation of inﬂammation, proliferation, differentiation, and
apoptosis, depending on cell type, and therefore represents a key
molecule in physiology [1]. The CaSR is also able to respond to a
variety of ligands, including polyvalent cations and amino acids.
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the receptor, making the CaSR uniquely capable of integrating several
metabolic signals. Activation of the CaSR by different ligands may
stabilise the CaSR in unique activation states allowing preferential
stimulation of different signalling pathways — termed “ligand-biased
signalling” [2].
Altered CaSR signalling is associated with a number of pathophysi-
ological states. In cancer, CaSR expression either becomes reduced or
even lost, or signalling pathways become activated that are different
from those activated in the respective normal tissues. The signalling
may differ dependent on the type of cancer, stage, grade, etc. Therefore,
there is need for a better understanding of how individual ligands
affect CaSR-mediated signalling, and how this will in turn beneﬁt
development of novel pharmaceutical therapies targeting the CaSR.
This review article aims to provide an overview of the signalling
mechanismmediated by the CaSR under normal physiological conditions
and in cancer.
1.1. CaSR signalling in physiology
The CaSR is a pleiotropic GPCR that is extremely sensitive to very
small deviations in plasma Ca2+o (i.e. less than 10%) within the
physiological range. There is a very steep, inverse sigmoid relationship
between Ca2+o and PTH release, with the steepest part of the curve
being centred around the physiological serum Ca2+o of 1.2 mM, at
which concentration PTH secretion is already suppressed by ~25% of
its maximal value [1].
Evidence gathered since the late 1980s showed that CaSR activa-
tion leads to inhibition of PTH via signalling mediated by the trimeric
G protein, Gαq/11. CaSR activation in the parathyroid glands andmany
other cellular systems promotes phosphoinositide turnover through
activation of membrane-bound phospholipase C (PLC), producing
inositol 1,4,5 tris-phosphate (IP3) and diacyl glycerol. These, in turn,
promote release of Ca2+ from intracellular, IP3-sensitive stores [3]
and protein kinase C (PKC) activation. Indeed, in mice lacking both
Gαq and Gα11 PTH levels are greatly elevated [4]. Genetic mutations
of the CaSR highlight the importance of this receptor for maintaining
divalent ion homeostasis [5–7].
The CaSR is also expressed in the colon where it plays an important
role in nutrient sensing and intestinal ﬂuid transport. Hebert et al.,
using isolated crypts from rat [8,9] and the CaSR−/−::GCM2−/−
knock out mouse model, demonstrated that intestinal ﬂuid secretion
involves CaSR-dependent degradation of cyclic nucleotides by phos-
phodiesterases [9], reversing the electrolyte secretory effect of cholera
toxin and enterotoxin. Further, it has been suggested that the presence
of the CaSR in enteric nerve cells, which interact with smooth muscle
along the colon, could indicate involvement of the CaSR in intestinal
motility [10].
Activation of the CaSR can also induce intracellular calcium (Ca2+i)
oscillations, which have been linked to inhibition of proliferation in co-
lonic epithelial cells [11]. Such CaSR-mediated Ca2+i oscillations have
been observed in a number of CaSR-expressing cells [12], including
parathyroid cells [13,14] and CaSR-expressing HEK293 cells
(HEK-CaSR) [15]. Recent work has examined how variations in CaSR-
mediated Ca2+i oscillation frequency and amplitude are physiologically
signiﬁcant in a variety of cell types. For example, in human colonic epi-
thelial cells the CaSR can induce two separate oscillatory pathways:
while CaSR-mediated high frequency (~3 to 4 min−1) sinusoidal
Ca2+i oscillations induce inhibition of proliferation, low frequency
(~1.5 min-1) transient Ca2+i oscillations do not [11]. Thus, the mecha-
nisms that control Ca2+i oscillation frequency and amplitude are critical
for various CaSR-dependent biological responses.
In HEK-CaSR cells, the sinusoidal oscillations (~4 min−1 at 37 °C)
[16,17] arise from the dynamic phosphorylation and dephosphorylation
of T888 [18–20], the primary PKC phosphorylation site of the CaSR [21].
Thus, receptor-induced activation of PKC leads to phosphorylation ofT888 to uncouple the receptor from Gαq/11-induced PLC activation and
Ca2+i mobilisation [21,22]. T888 is then dephosphorylated by protein
phosphatases to restore receptor coupling to PLC andCa2+imobilisation
[20]. Interestingly, T888 phosphorylation exhibits a bi-phasic, ‘bell-
shaped’ proﬁle in which phosphorylation of T888 peaks at Ca2+o
concentrations around 2–3 mM [20]. Further increases in Ca2+o lead
to decreases in T888 phosphorylation, and Ca2+o concentrations≥
4.0 mM elicit sustained elevations in Ca2+i rather than Ca2+i oscilla-
tions [20]. Disruption of the T888 PKC phosphorylation site produces
an increase in Ca2+o sensitivity and recently the mutation T888M was
identiﬁed in a case of Autosomal Dominant Hypocalcemia (ADH) [23],
demonstrating that the T888 residue and its regulation by PKC is critical
for physiological CaSR function in vivo.
In addition to phosphoinositol turnover, the CaSR also couples to a
number of other signalling pathways. For example, in thyroid C cells
activation of the CaSR is linked to calcitonin-secretion through the ac-
tivation of voltage-gated calcium channels [24], while in kidney cells,
CaSR activation is coupled to the metabolism of arachidonic acid by
cytochrome P450 (CYP450) and cyclooxygenase (COX) pathways
via a Gi-dependent mechanism [25].
CaSR activation is linked also to pro-proliferative stimuli in many
cell systems. The regulation of pro-proliferative CaSR signalling in-
volves activation of the mitogen-activated protein (MAP) kinases
extracellular-signal-regulated kinases (ERK) and p38MAPK protein ki-
nases [26,27]. High Ca2+o induces CaSR-mediated activation of ERK1/
2 in bovine parathyroid and HEK-CaSR cells, and the calcimimetic
NPS-R467 markedly enhances this effect [28,29]. L-amino acids have
only a relatively small effect, possibly operating as a ﬁne-tuning
mechanism [30]. Classically, ERK1/2 is activated via Ras-dependent
activation of MAP kinase kinase (MEK), and speciﬁc inhibition of
MEK suppresses high Ca2+o-induced ERK1/2 activation in both bo-
vine parathyroid and HEK-CaSR cells [28].
ERK1/2 appears to be a signiﬁcant site of signal convergence
downstream of CaSR activation, as pertussis toxin, the PLC inhibitor
U73122 and PKC inhibitor GF109203X, have all been shown to inhibit
ERK1/2 activation partially implying a role for Gαi, as well as Gαq/11
and PI-PLC [28,29]. CaSR-mediated activation of ERK1/2 via Gαi also
requires dynamin/β-arrestin-independent receptor internalisation
[29]. In addition, CaSR-mediated ERK phosphorylation can also
occur through “triple-pass” signalling in which CaSR activation leads
to the release of an epidermal growth factor (EGF)-like peptide
by matrix metalloproteinases, which in turn evokes EGF receptor-
mediated cell signalling [31].
2. CaSR in cancer: tumour suppressor or oncogene?
Intracellular Ca2+-dependent signalling mechanisms are frequently
remodelled or deregulated in cancer cells. The current understanding is
that the CaSR can either prevent, or promote tumourigenesis depending
on the type of cancer [32] (see also Table 1). The mechanisms behind its
impact on carcinogenesis are multiple and not well understood.
The expression of the CaSR can be decreased or even absent, as it is
in parathyroid and colorectal cancer. It has been shown recently that
the CaSR is expressed in differentiated neuroblastic tumours, but it is
silenced in unfavourable neuroblastomas [33]. In these tumours,
dearth of CaSR expression results in loss of the growth suppressing ef-
fects of high levels of Ca2+o. Activation of the receptor inhibits prolif-
eration of these cancer cells, suggesting a tumour suppressor function
for CaSR. In contrast, increased expression is observed in highly met-
astatic primary breast and prostate cancer cells. Furthermore, in
breast cancer cells CaSR activates preferentially Gαs proteins and
not Gαi, as in normal breast cells [34], resulting in increased produc-
tion of parathyroid hormone-related peptide (PTHrP), which is con-
sidered a primary cause of hypercalcaemia of malignancy, and a
contributor to metastatic processes involving bone. In these settings,
the CaSR seems to have an oncogenic role (Table 1).
Table 1
The CaSR in cancer (adapted from Chakravarti et al. [182]).
Cancer type Expression of the CaSR Effect of CaSR
Parathyroid adenoma/carcinoma Decreased Inhibits proliferation
Colorectal cancer Decreased Inhibits proliferation
Enhances differentiation
Neuroblastoma Expressed in favourable tumours
Gliomas Enhances proliferation
Breast cancer Increased expression in metastasising tumours Facilitates metastasis to bone (through PTHrP)
Prostate cancer Facilitates metastasis to bone (through PTHrP)
Leydig cancer cells Enhances proliferation
Ovarian cancer Enhances proliferation
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signalling by regulation of cell migration. Indeed, CaSR-dependent
ERK phosphorylation requires receptor binding to the cytoskeletal
protein ﬁlamin A, while CaSR activation in breast cancer cells evokes
rho-dependent actin ﬁlament formation through Gα12/13 [35]. Since
Gα12/13 proteins have been implicated in many different processes,
including cell migration [36], it has been hypothesised that CaSR-
dependent signalling in breast and prostate cancer cells could favour
the metastatic spread of tumours (a concept that is discussed further
below) [37].
Another mechanism leading to altered signalling through the CaSR
is loss of one or more signalling partners (e.g. Gαq in parathyroid tu-
mours). In some organs, as the gut, the CaSR is activated by a plethora
of different ligands, such as spermine, amino acids, etc. The impact of
changes in CaSR ligand concentration in the extracellular milieu on
the activation of speciﬁc signalling pathways (as it might be the
case in the intestinal tract) also requires further investigation. There
is no evidence as yet that mutations of the CaSR play a role in
tumourigenesis.
Changes in CaSR signalling during tumourigenesis seem to involve
very different pathways, depending on the type of cancer, the tissue/
cells involved, consistent with the different roles the CaSR plays in
normal physiology.
Pharmacological agonists and antagonists of the receptor might ﬁnd
a much broader therapeutic usage, depending on whether activation or
inhibition of the receptor is required, but ﬁrst we have to understand in
more detail the mechanisms driving CaSR signalling in the different
tissues.
2.1. The role of the CaSR in parathyroid tumourigenesis
Parathyroid adenoma, parathyroid hyperplasia and parathyroid
cancer are the main disorders of the parathyroid glands. Parathyroid
adenoma and cancer lead to primary hyperparathyroidism (pHPT).
pHPT is a relatively common endocrine disorder, with 25–30 new
cases per 100,000 people each year [38]. Parathyroid adenomas
account for 80% of the pHPT cases, whereas parathyroid cancer is an ex-
tremely rare disease responsible for less than 1% of all pHPT cases [38].
Parathyroid adenomas are more frequent in 42- to 59-year-old women,
while parathyroid carcinoma develops usually much later in life with
equal frequency in both sexes. No dietary or lifestyle factors are
associated with the risk to develop parathyroid cancer [39]. The CaSR
mRNA and protein expression levels were found to be decreased or
lost in parathyroid adenomas and carcinomas. Whether this is the
effect or cause of the tumourigenesis is not yet clear.
2.1.1. Expression of the CaSR in parathyroid tumours
Several studies have demonstrated that the expression levels of
CaSR mRNA and protein are decreased in parathyroid adenomas, as
well as in hyperplastic parathyroid glands from patients with uremic
secondary hyperparathyroidism, compared with normal glands
[40–42]. In addition, the study of Haven et al. suggests a role for the
CaSR in prevention of malignant parathyroid tumours as the CaSRexpression is decreased or absent in parathyroid carcinomas, com-
pared with parathyroid adenomas and hyperplastic glands [43].
The molecular mechanisms that drive the loss of CaSR expression,
as well as the mechanisms underlying abnormal PTH secretion in
response to Ca2+o, in parathyroid tumours are still not completely
understood. One possible explanation for the loss of CaSR expression
was the loss of CaSR allele(s) on chromosome 3q leading to decreased
CaSR mRNA levels observed in pathological parathyroid glands, how-
ever, this has turned out not to be the case [42,44]. Furthermore, no
mutations in the coding region of the CaSR have been identiﬁed in
parathyroid adenomas, hyperplasia or carcinomas, suggesting that
mutations are not involved either in loss of CaSR expression or abnor-
mal PTH release in these tissues [44].
2.1.2. CaSR-mediated signalling in parathyroid tumours
Uncontrolled parathyroid cell proliferation is a common feature in
pathological parathyroid glands. Physiological activation of the CaSR
appears to be related with suppression of parathyroid proliferation
[5,43,45]. Patients with inactivating CaSR mutations and mice homo-
zygous for the CaSR knockout generally exhibit marked parathyroid
hyperplasia, indicative of the inhibitory role of the CaSR in parathy-
roid cell proliferation [5]. Furthermore, Haven et al. showed that the
Ki67 proliferation index is signiﬁcantly higher in parathyroid carcino-
mas, where it is signiﬁcantly correlated with down-regulation of CaSR
expression, than in parathyroid adenomas and hyperplastic lesions
[43].
The inhibitory role of the CaSR in parathyroid proliferation was
demonstrated by using calcimimetics, allosteric activators of the
CaSR. Recent work by Miller et al., in a rodent model of chronic kidney
disease characterised by parathyroid hyperplasia and excessive PTH se-
cretion, showed that treatment with the calcimimetic cinacalcet medi-
ated regression of parathyroid hyperplasia and PTH decrease, which
could be reversed by discontinuation of the treatment. These data fur-
ther support the need of an active CaSR for inhibition of parathyroid
proliferation [46]. Interestingly, calcimimetics not only activate the
CaSR but seem to be able to increase its expression as well. Studies in
subtotally nephrectomised rats showed an increase in CaSR mRNA
and protein levels after administration of the calcimimetic NPS-R568.
In addition administration of the calcimimetic AMG 641 increased
CaSR transcription and was able to prevent decrease of CaSR protein
expression [47,48].
Impaired signalling through the CaSR is considered to be a major
factor in promoting parathyroid hyperplasia and abnormal Ca2+o
sensing. As some parathyroid adenomas show a reduced sensitivity
to Ca2+o even when CaSR expression levels are normal, loss of CaSR
expression might not be the only factor involved in the abnormal
PTH secretion in parathyroid adenomas [40,49]. A number of possible
candidates have been proposed that could interact with the CaSR and
modulate its signalling, such as cyclin D1, regulator of G protein sig-
nalling 5 (RGS5), caveolin-1, and Gαq protein.
Cyclin D1 belongs to the cyclin protein family and is involved in
regulation and progression of the cell cycle. It is overexpressed in
20–40% of parathyroid adenomas and in a subset of the tumours
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to a chromosomal rearrangement and, as a result, it is overexpressed
[50,51]. Furthermore, overexpression of cyclin D1 may also be attrib-
uted to a misregulation of the wingless (Wnt) / β-catenin signalling
pathway, leading to accumulation of non-phosphorylated β-catenin
in the cytoplasm and nucleus in a PTH-producing parathyroid tumour
cell line [52]. Whether in the parathyroid cyclin D1 expression is
modulated by CaSR-dependent regulation of the Wnt pathway, as
seen in colonocytes, is currently not known.
It has been suggested that cyclin D1 can interact with the CaSR and
support development of parathyroid tumours by increasing para-
thyroid proliferation [53]. The role of cyclin D1 in parathyroid
tumourigenesis is supported by the study of Imanishi et al. [50], who
reported that a transgenic mouse model of hyperparathyroidism, that
mimics the overexpression of cyclin D1 in parathyroid adenomas,
presented with decreased CaSR expression levels, increased parathy-
roid cell proliferation and a right-shift in Ca2+o-dependent PTH re-
sponse [50,54]. Furthermore, Corbetta et al. [53] showed that in
parathyroid adenomas the CaSR inhibits cyclin D1 expression in the
presence of growth factors, such as basic ﬁbroblast growth factor
(bFGF) and EGF, preventing the oncogenic actions of cyclin D1 in
these tumours. Interestingly, the CaSR was unable to inhibit cyclin D1
activation in the absence of bFGF and EGF, supporting the existence
of an interaction between the CaSR and these growth factors [53].
Koh et al. have recently shown that RGS5 is up-regulated in parathy-
roid tumours when compared with normal parathyroid glands [49].
RGS5 is part of the R4 subtype of the RGS proteins that inhibit signal
transduction through regulation of heterotrimeric G proteins. Class C
GPCRs, including the CaSR, are regulated by RGS proteins. In HEK-CaSR
cells, transiently expressing RGS5, ERK1/2 phosphorylation was
inhibited, indicating that RGS5 is able to inhibit CaSR signal transduction
in this heterologous expression system. Furthermore, RGS5−/− knock-
out mice displayed abnormally low plasma PTH levels with normal
Ca2+ serum levels and normal responsiveness to Ca2+o. Therefore, it
has been suggested that the RGS5 is a negative regulator of CaSR activity
in parathyroid cells. It seems that RGS5 may compete with the CaSR in
binding to Gαi and Gαq proteins preventing CaSR activation and thus
maintaining the sensitivity of the receptor to deviations from normal
Ca2+o levels. Furthermore, overexpression of RGS5 in parathyroid ade-
nomas inhibited normal CaSR signalling and contributed to the abnor-
mal Ca2+ sensing observed in parathyroid tumours. However, the
normal Ca2+ serum levels present in the RGS5−/− mice indicate that
the absence of RGS5 may not create a complete opposition to CaSR
activity as it is seen in genetic conditions such as autosomal dominant
hypocalcemia (ADH) and CaSR−/− mice [49].
In many cell types, e.g. bovine parathyroid cells, the CaSR is found
in caveolae, a plasma membrane organelle. Caveolin-1 is a major
component of caveolae and is thought to inhibit signal transduction
and proliferation. Approximately 62% of parathyroid adenomas
express caveolin-1, and these tumours appear to have a better PTH
response to Ca2+o compared with those where caveolin-1 expression
is lower or lost [55]. Studies by Kifor et al. [55] have shown in freshly
isolated bovine parathyroid cells that activated ERK 1/2 colocalises
with caveolin-1 at the plasma membrane, whereas in bovine parathy-
roid cells cultured for 10 days they observed translocation of activat-
ed ERK1/2 and caveolin-1 to the nucleus and cytosol, in parallel with
decreased expression of caveolin-1. ERK1/2 activation was increased
both at low and high Ca2+o in bovine cells cultured for 10 days,
which is in accordance with the possible role of caveolin-1 as a nega-
tive regulator in the MAPK cascade. Similarly, in parathyroid adeno-
mas, where caveolin-1 expression is decreased or lost, ERK1/2 was
localised in the cytosol and nucleus, and a reduced ability for high
Ca2+o-mediated suppression of PTH secretion was observed. In the
majority of the adenomas ERK1/2 was activated independently of
Ca2+o [55]. Thus, contrary to bovine parathyroid glands, ERK1/2
signalling pathway appears to be lost in parathyroid adenomas.Corbetta et al. have reported that Gαq protein levels were lower in
pathological parathyroid glands than in normal glands [40]. These
results are supported by another study in which increasing Ca2+o con-
centrations and the CaSR agonist, gadolinium (Gd3+), failed to activate
ERK1/2 in parathyroid adenomas [56]. Consequently, in parathyroid
adenomas low expression of caveolin-1 and Gαq protein levels could
possibly cause altered PTH release in response to Ca2+o [40,55].
In conclusion, parathyroid tumours are characterised by decreased
CaSR expression levels, increased cell proliferation and abnormal PTH
secretion. Although the exact mechanisms that lead to these events
are still unknown, a number of studies have suggested that the CaSR
plays a role in these processes, including CaSR-mediated modulation
of cyclin D1 expression and abnormal CaSR signalling due to RGS5
overexpression in these tumours. In addition, CaSR-induced activation
of ERK1/2 signalling does not seem to be active in parathyroid tumours.
Further studies are needed to fully understand the mechanisms re-
sponsible for the development of parathyroid tumours and the possible
CaSR signalling mechanisms in this process.
2.2. The role of CaSR in colorectal tumourigenesis
The CaSR seems to play an important protective role in colorectal
cancer. Colorectal cancer is the fourth most frequent form of cancer in
men and the third in women worldwide [57,58]. Diet plays a major
role in colorectal tumourigenesis and epidemiological studies show
an inverse correlation between calcium intake and the risk of tumour
development [59]. Calcium exerts its chemopreventive features
through a plethora of mechanisms, such as binding toxic secondary
bile acids and/or ionised fatty acids and neutralising them in form
of insoluble calcium soaps [60,61], or by activating several down-
stream signalling cascades such as stimulating cell differentiation,
inducing apoptosis and inhibiting proliferation [62–64]. There is
evidence that some of these molecular mechanisms are mediated, at
least in part, by the CaSR [65–68].
2.2.1. Expression of the CaSR in the colon
In 1991, Whitﬁeld [69] hypothesised that the Ca2+o concentration
in the lumen of colonic crypts increases from sub-physiological levels
at the base reaching physiological or even higher levels at the top. Cell
proliferation is driven by the combination of several factors in the
lower two-thirds of the crypt while proliferation is stopped and
differentiation is triggered when the cells reach a critical level in the
Ca2+o concentration. In a later review, Whitﬁeld hypothesised that
it is the CaSR that senses the changes in Ca2+o levels and acts as a mo-
lecular switch that turns off proliferation and turns on differentiation
in colonocytes [70,71].
Furthermore, besides calcium, there are numerous other CaSR
ligands (like polyamines, amino acids) in the gastrointestinal tract,
ingested through the diet or produced by local bacterial microﬂora
that might alter the responsiveness of the receptor to Ca2+o. These li-
gands activate a wide spectrum of signalling pathways in a cell speciﬁc
manner.
Although the CaSR is present along the entire length of the diges-
tive tract [72], the exact localisation and expression pattern in the
colon is not clear. Published data are discordant. Chattopadhyay and
colleagues [10] have shown that the CaSR is expressed in different
regions of the rat colon, including the basal region of the crypt, the se-
rosa, sub mucosa and also in the nerve endings around the myentric
plexus. Sheinin et al. [73] found that the CaSR was present only in
the entero-endocrine cells of the human colonic crypt. Later, Cheng
et al. [8] showed cytoplasmic and membrane expression of the CaSR
protein in rat and human colonic epithelial cells both at the top
and base of the crypt and in the enteric nervous system [74].
Chakrabarty and his colleagues detected perinuclear CaSR expression
in the columnar epithelial cells of the colonic crypt, and showed an
increase in CaSR expression along the crypt axis, from the basal
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found the highest expression of the CaSR at the base of the crypt,
decreasing towards the apex [77].
A clear consensus regarding the expression of the CaSR protein in
the colon is needed to validate Whitﬁeld's hypothesis. Similarly, the
existence of a Ca2+o gradient seems to be a hypothesis based on
Ca2+i concentrations in colonocytes lining the crypt [8,78]. The exis-
tence of a gradient in the crypt lumen also needs to be veriﬁed.
Contrary to the inconsistent data of protein expression pattern in
the normal colon, there is a consensus that the CaSR expression is
down-regulated during colorectal tumourigenesis [73,75,76,79] just
as in parathyroid tumours. The underlying mechanisms leading to
this loss of expression are not completely understood.
Epigenetic alterations such as DNAmethylation and histonemodiﬁ-
cations, which are frequent events in tumours [80], might cause silenc-
ing of the CaSR gene, as suggested by Hizaki et al. [79]. In normal cells
DNA methylation assures regulation of proper gene expression and
generally affects cytosines within CpG islands [81], regions of the
DNA with clusters of cytosines followed by guanine [82]. The CaSR
has two promoters and two 5′-untranslated exons (exon 1A and
exon 1B) yielding alternative transcripts, but encoding the same pro-
tein [83,84]. The upstream promoter contains a TATA and a CAAT box
and only few sporadic CpGs, whereas the downstream promoter con-
tains a large CpG island that could be susceptible to methylation
[83,84].
Interestingly, it seems that exon 1A might have more impact in
regulating the expression level of the CaSR then exon 1B. In parathy-
roid adenomas the expression of exon 1A was much lower than in the
normal gland [83]. Similarly, in colorectal tumours exon 1A mRNA ex-
pression correlated inversely with tumour grade [85] while expres-
sion of exon 1B did not change signiﬁcantly.
Several transcription factor binding sites like vitamin D response el-
ements (VDRE), and NFкB, Stat1/3, Sp1/3 binding sites are located in
both CaSR promoters [84,86,87]. The two VDREs in the CaSR promoter
suggest a role for vitamin D in regulating CaSR expression. Indeed, in-
jection of the active vitamin D metabolite, 1,25-dihydroxyvitamin D3,
in rats resulted in an enhanced CaSR expression in the parathyroid
glands, thyroid and kidneys [84]. Similar results were observed also
in the human colon cancer cell line CBS [75]. Whether lower levels of
the vitamin D receptor in colorectal tumours could be one cause of
decreased CaSR expression in these tumours [88], needs to be proven.
2.2.2. CaSR-mediated signalling in colon cancer
The CaSR is linked to an intricate network of calcium signalling
pathways that control normal and cancer cell growth, depending on
cell-speciﬁc coupling to appropriate G proteins. High Ca2+o levels re-
duce the rate of proliferation in numerous colon cancer cell lines
[65,89]. The signalling cascade seems to begin with inhibition of
phospholipase A2 [85] leading to reduced levels of arachidonic acid,
precursor of the proliferative prostaglandins (e.g. prostaglandin E2).
Activation of the CaSR sustains differentiation in several colon cancer
cell lines [66,89,90]. This has been suggested to be dependent on
PKC-regulated c-myc down-regulation [65,91] and mediated via the
MAP kinase pathway [89].
Chakrabarty et al. have shown that in several colon cancer cell
lines Ca2+o increases expression of the tumour suppressor
E-cadherin [76]. As an intercellular adhesion protein the major role
of E-cadherin is maintenance of intact cell–cell contacts for which
E-cadherin complexes with ß-catenin, reducing its availability to
translocate into the nucleus. In the nucleus the role of ß-catenin is
to activate, together with TCF4, the so-called canonical Wnt pathway
(for rev. see [92,93]).
The Wingless (Wnt) pathway is crucial for the maintenance of
both foetal and adult intestinal crypt architecture and is one of the
main pathways regulated by Ca2+o in the colon [93–97]. The adeno-
matous polyposis coli (APC) protein, a major component of the Wntpathway, is altered in more than 80% of colorectal tumours, leading
to accumulation of ß-catenin in the nucleus [94,98]. Extracellular cal-
cium inhibits the canonical Wnt pathway by preventing nuclear
translocation of ß-catenin, reducing β-catenin-TCF4 complex forma-
tion, downregulating c-myc and cyclin D1 expression and thus
inhibiting proliferation in colon cancer cell lines, an effect mediated
at least in part by the CaSR [76] (Fig. 1). Rey et al., using an intestine
speciﬁc CaSR−/− mouse model, have recently shown that colonic
crypts lacking the CaSR have increased proliferation rate and higher
nuclear β-catenin levels, and that absence of the CaSR allows phos-
phorylation of β-catenin at Ser-552/675, which promotes its nuclear
translocation [67].
Activation of CaSR by increased Ca2+o mediates Wnt5a secretion
from colonic myoﬁbroblasts. Ca2+o also enhances Wnt5a secretion
in HT-29 colon cancer cells expressing truncated APC, leading to inhi-
bition of the defective Wnt signalling in these cells [97,99]. In colon
cancer cells CaSR activation led to upregulation of the receptor tyro-
sine kinase-like orphan receptor 2 (Ror2) protein which acts as a re-
ceptor for Wnt5a [97]. Taken together, it is proposed that the
CaSR-mediated overexpression of Ror2 leads to the Wnt5a-mediated
inhibition of β-catenin signalling in these cells [97,99,100] (see also
Fig. 1). Although Wnt5a can be considered a tumour suppressor,
there is also evidence for its involvement in metastasis, as seen in
melanoma cells [92].
Furthermore, interactions between CaSR-mediated stromalWnt5a
and epithelial Ror2 in colonic epithelial cells seem to increase caudal
homeobox type 2 (CDX2) production suggesting that activated CaSR
stimulated epithelial differentiation through Wnt5a-mediated non-
canonical Wnt signalling [97]. The homeobox gene CDX2 stimulates
expression of sucrase-isomaltase, liver-intestine cadherin and mucin2
in intestinal epithelial cells, regulating cell growth and differentiation
[97,101]. A number of studies illustrate that the CDX2 expression is
clearly reduced in colon cancer [97,102,103], probably as a result of
loss of CaSR expression (see Fig. 1).
The anti-proliferative effect of Ca2+o seems to be lost in transformed
cells during colon carcinogenesis [104,105]. Therefore, it is of para-
mount importance to ﬁnd molecular markers that would identify
whether a subject would beneﬁt from calcium supplementation or
whether high calcium intake would inhibit only the growth of normal
cells while supporting proliferation of malignant cells. The CaSR could
be this marker, however this still needs scientiﬁc proof.
Our knowledge regarding CaSR signalling is still very basic. The
exact, step-by-step signalling in colon cancer cells, including other
signalling systems involved, is still unravelled. Considering the diver-
sity of ligands present in the colon and the phenomenon of biased sig-
nalling as depicted in Fig. 3, we need better models and systems to
understand the role of the CaSR in normal intestinal physiology and
in the process of colon tumourigenesis.
2.3. The role of the CaSR in breast and prostate tumourigenesis
Calcium and the CaSR are considered to be involved in both breast
and prostate cancer development as well as in the formation of bone
metastasis. Breast and prostate cancer are the most frequent malignan-
cies, with one in every 8 women and one in every 6 men born in the
United States today to be diagnosed with breast or prostate cancer re-
spectively [106]. Nutritional factors, amongst others dietary calcium,
are considered to modulate the risk of breast and prostate cancer. The
anti-tumour effects of calcium involve regulation of cell proliferation,
differentiation, and apoptosis, partially mediated through interaction
with the vitamin D system (reviewed in [107]). However, in contrast
to colorectal cancer [108], there is no conclusive evidence to date for
the cancer preventive effects of dietary and/or supplemental calcium in-
take in breast [109–115] and prostate cancer patients [116]. The under-
lying mechanisms of whether and how calcium inﬂuences the risk of
breast or prostate cancer are not yet elucidated.
Fig. 1. Regulation of growth control mediated by calcium sensing receptor in colonocytes. The CaSR can be activated by several ligands in the extracellular mileu of the colonocytes
which regulate proliferation and differentiation in these cells. There is cross talk between myoﬁbroblasts and colonocytes. Upon receptor activation, Wnt5a is secreted by the
myoﬁbroblasts. Wnt5a then (i) increases the expression of Ror2, a receptor for Wnt5a. Upon Wnt5a-Ror2 binding, differentiation is promoted by signalling cascades leading to reg-
ulation of genes like Cdx2, sucrase isomaltase (SI) and villin (green) (ii) The Wnt5a-Ror2 binding can further inhibit nuclear translocation of β-catenin (red) or leads to degradation
of β-catenin by upregulation of Siah-2, a ubiquitination ligase (orange) regulating the transcription of genes like cyclin D1, C-myc, PCNA and/or replication licensing genes, thus
inhibiting proliferation. (iii) A third mechanism of growth control is by activation of myoﬁbroblast-CaSR which increases secretion of Dickkopf-related protein 1 (Dkk-1) which
then inhibits downstream signalling of its receptor, frizzled, inhibiting Wnt signalling(blue) [178–180].
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The CaSR is expressed in the ductal epithelial cells of normal
breast tissue [117] where it is involved in regulating calcium concen-
trations in the breast milk during lactation via modulation of PTHrP
secretion [118]. Moreover, both ductal and lobular carcinomas
express the CaSR. Interestingly, its highest expression was observed
in breast cancer patients with bone metastasis, making the authors
hypothesise that CaSR-positive tumours are more likely to
metastasise to the skeleton [119]. In accordance with this hypothesis,
expression of the CaSR was higher in breast cancer cells with relative-
ly increased bone metastatic potential (MDA-MB-231) compared
with cell lines showing lower tendency to metastasise to bone
(MCF-7, T47D) [120]. Besides breast cancer cells, CaSR mRNA and
protein was detected also in the highly bone metastatic prostate can-
cer cell lines PC-3 and C4-2B as well as in the non-metastatic LNCaP
cells, albeit at a lower level [121,122]. So far, no reports on expression
of the CaSR in normal prostate tissue or prostate cancer patients are
available.
Currently, the mechanisms causing altered expression of the CaSR
in breast cancer are not known. A constitutive activation of Nuclear
Factor-kappaB (NFκB) has been observed in breast cancer [123,124]
and might contribute to increased transcription of the CaSR gene,
which has functional kappa b elements [86]. CaSR promoters are
also known to have vitamin D responsive elements, which allow
regulation of CaSR gene expression by 1,25-dihydroxyvitamin D3, as
observed in parathyroid glands [84]. In breast malignancies, however,
the availability of the active vitamin D metabolite might be reduced
as a result of an altered expression of the activating and degrading
vitamin D enzymes (reviewed in [125]), which would lead to a
decrease in the CaSR expression. Moreover, transactivation of the
EGFR by the CaSR has been reported [126], however, it remains spec-
ulative whether there is a reciprocal transactivation and whether this
has an impact on the expression level of CaSR, as it was observed for
the oestrogen-sensitive class C G-protein coupled receptor, GPR30
[127]. Whether epigenetics, gene ampliﬁcation or alterations in
CaSR trafﬁcking [128] modulate the expression of the CaSR in breast
cancer remains to be investigated.2.3.2. CaSR-mediated signalling in breast and prostate cancer
CaSR stimulation by high Ca2+o levels promoted proliferation of
MCF-7, PC-3 and C4-2B breast and prostate cancer cells known to
metastasise to the skeleton. Whereas in MCF-7 breast cancer cells,
Ca2+o-induced cell proliferation appears to be linked to ERK1/2 phos-
phorylation, which in turn stimulates expression of the Transient Re-
ceptor Potential Canonical 1 (TRPC1) cation channel and subsequent
calcium entry [126,129], in PC-3 cells, Cyclin D1 is associated with the
Ca2+o-induced proliferative effect [122]. In contrast, Ca2+o did not af-
fect proliferation of non-bone-metastatic LNCaP prostate cancer cells
[122]. The effects of Ca2+o on proliferation in these cells are likely me-
diated by the CaSR, as its knockdown by shRNA or siRNA decreased
Ca2+o-induced cell proliferation in PC-3 and MCF-7 cells in vitro. It has
been suggested that physiological concentrations of Ca2+o (1.4 mM)
would reduce breast cancer cell proliferation compared with low con-
centrations of Ca2+o (between 0.175 and 0.2 mM), proposing the
CaSR as a tumour suppressor in MCF-7 andMDA-MB-435 breast cancer
cells, similar to BRCA1 [130]. These ﬁndings might be due to i) a
dose-dependent biphasic response of the CaSR to Ca2+o and/or ii) a
switch in the G-proteins, as shown for CaSR-dependent regulation of
PTHrP secretion inMCF-7 and Comma-D cells [34]. Furthermore, prolif-
eration under higher concentrations of Ca2+o was not tested in absence
of vitamins, peptones and amino acids, since some of these might have
been responsible for “ligand biased signalling” of the CaSR, as described
later in the present review (Section 3.2).
2.3.3. The CaSR in bone metastasis
In advanced breast and prostate cancer, the CaSR seems to play a
key role in the development of bone metastasis. For both types of can-
cer the preferential site of metastasis is the skeleton. Approximately
70% of patients with advanced breast cancer develop bone metastases
with a predominantly osteolytic phenotype, while prostate cancer
mostly forms osteoblastic bone metastases [131]. For both types of
metastases, it is believed that breast or prostate cancer cells and
bone cells communicate with each other, thereby triggering a vicious
circle that results in progressive bone destruction and/or tumour
growth as depicted in Fig. 2.
Fig. 2. The vicious circle of bone metastasis in breast and prostate cancer. Breast and prostate tumours produce parathyroid hormone related peptide (PTHrP) which up-regulates
receptor activator for NFκB ligand (RANKL) on osteoblastic and stromal cells. Upon binding of RANKL to its receptor on osteoclast precursor cells, i.e. Receptor activator for nuclear
factor κB (RANK), maturation and differentiation of osteoclast precursors to activated osteoclasts is initiated and bone resorption stimulated. During bone resorption, large amounts
of calcium (Ca2+) as well as diverse growth factors are released. Calcium promotes further PTHrP production in the tumour, thereby supporting the vicious circle. Acting via the
calcium sensing receptor (CaSR), Ca2+ is considered to act as a chemoattractant factor and to facilitate tumour cell migration into the bone. Growth factors enable tumour cell
survival and growth in the bone microenvironment and in consequence the manifestation of bone metastases which in turn increases the rate of bone turnover, thus feeding
the vicious circle.
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resorption. In this regard, PTHrP is considered one of the major fac-
tors that promote bone turnover via up-regulation of Receptor Acti-
vator of NFκB Ligand (RANKL) in osteoblasts. Binding of RANKL to
its receptor RANK (Receptor Activator of NFκB), which is expressed
by cells of the osteoclastic lineage, increases the development, activi-
ty, and survival of mature osteoclasts in both physiological and path-
ological circumstances [132,133]. PTHrP is expressed in both primary
breast tumours and, to a higher extent, in bone metastases of breast
tumours [134]. It is therefore suggested to act both in an endocrine
and paracrine manner. Endocrine secretion of PTHrP by the cancer
cells at the primary tumour site may result in so-called hypercalcemia
of malignancy, which occurs in up to 30% of cancer patients and is at-
tributable to excessive bone resorption (reviewed in [135]). On the
other hand, PTHrP is likely produced by metastatic cancer cells locally
in the bone, where it stimulates bone resorption in a paracrine man-
ner thereby allowing tumour expansion. In normal breast epithelial
cells, PTHrP secretion is subject to a negative feedback regulation by
calcium [136]. However, this negative feedback regulation is lost in
both malignant breast (MCF-7, MDA-MB-231) and prostate cells
(LNCaP and PC-3), where activation of the CaSR stimulates PTHrP se-
cretion [137,138]. The effect of Ca2+o on PTHrP secretion is potentiat-
ed by transforming growth factor-beta (TGF-β) [121,137]. Recently,
Mamillapalli et al. demonstrated that a shift from Gαi to Gαs binding
was responsible for the CaSR-dependent stimulation of PTHrP secre-
tion in Comma-D and MCF-7 cells, instead of the inhibitory effect ob-
served in normal mammary epithelial cells [34].
Circulating cancer cells are believed to sense calcium from bone
through the CaSR by a mechanism which is not yet clearly understood.
The activation of the CaSR might promote the retention and colonisa-
tion of these cells in the bone. This hypothesis is strongly supported
by the ﬁndings of Liao and colleagues, who used an intra-cardiac injec-
tionmodel and demonstrated that the CaSR is essential for prostate can-
cer cells to develop bone metastases in mice. They provided evidence
that in vitro, Ca2+o stimulates prostate cancer cell proliferation andenhances the attachment of these cells via the CaSR and Akt signalling
[122], probably promoting their metastatic properties. Moreover, the
fact that highly-bone metastatic MDA-MB-231 breast cancer cells
showed a stronger CaSR-dependent migratory response to Ca2+o com-
pared with cells with a lower metastatic potential (MCF-7, T47D) [120],
strongly supports the role of the CaSR inmigration of these cancer cells.
Thus, calcium should be considered as a bone-derived chemoattractant
factor similar to RANKL [139] and stromal cell-derived factor-1 (SDF-1)
[140,141]. As previously shown by Kang and colleagues, metastatic
breast cancer cells seem to be a subpopulation of primary tumour
cells which, through genetic alteration, acquire features allowing prolif-
eration, invasion, neovascularisation and ﬁnally metastatic capabilities.
They even obtain the ability to inﬂuence bone remodelling to their ad-
vantage [142]. An adaptation of breast cancer cells seems to be essential
for them to survive in such a hostile environment and it can be speculat-
ed that only a fewhighly adaptedmetastatic cells are needed to produce
bone lesions. Up-regulation of the CaSR in breast cancer could be part of
this adaptation. To address this issue, studies on the expression of CaSR
in bone metastatic specimens are urgently needed. Clearly, our under-
standing of how the CaSR is involved in the development of bone
metastasis is very limited and warrants further investigation. Future
studies might also focus on the effect of CaSR activation onWnt signal-
ling, which has been implicated in bone metastasis [143].
3. The downstream signalling network of CaSR
The CaSR is a complex receptorwith a plethora of ligands, participat-
ing in numerous different intracellular signalling pathways. Signal pro-
cessing occurs already at the receptor level [144,145]. The CaSR has
several orthosteric agonists and its activity is modulated by a large vari-
ety of allosteric modulators [146]. The binding of those extracellular
compounds to the CaSR induces intracellular signalling via three differ-
ent G proteins. Themolecularmechanisms endowing the CaSRwith the
possibility to activate preferentially one speciﬁc G protein upon binding
a particular ligand, without activating others are not completely
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intracellular phosphorylation of the CaSR at T888. Many of the dynamic
and spatial aspects of CaSR signalling are undoubtedly underappreciat-
ed. For a number of other signalling systems dynamic and spatial as-
pects have turned out to be of key importance for understanding the
signalling process [147,148]. Real-time dynamic measurement of the
signalling activity of the receptor, using for instance ﬂuorescence reso-
nance energy transfer (FRET) [149,150], would ensure a better under-
standing of the dynamic competition of the G proteins for binding to
the receptor and, perhaps, indicate how the receptor achieves ligand-
biased signalling via modulation of its afﬁnity for the target G proteins.
In addition, to such short-termdynamic investigations of receptor activ-
ity, phosphoproteomics [151,152] or reverse phase protein arrays [153]
could be used at a much slower time scale to elucidate how signalling,
induced by the CaSR, propagates through the signalling network and
controls various cellular processes, such as cell motility and gene
expression. Such studies can go hand in hand with computational
modelling efforts to study how signalling dynamics emerges from the
kinetics of protein-protein interactions [154].
3.1. Mathematical modelling of the CaSR
One approach to tackle the mechanisms underlying ligand-biased
signalling is to study the CaSR using biochemical models of cooperative
proteins. Multi-protein complexes, such as the CaSR can display
cooperativity, allostery and conformational transitions, central attri-
butes of GPCRs [155]. Cooperativity and conformational changes are
biochemical mechanisms that confer sensitisation towards signals; in
the limit of strong cooperativity the saturation of a receptor with a
signal is described by a sigmoidal Hill-type equation. Allostery is the
phenomenon that one signal can inﬂuence the GPCR afﬁnity for anoth-
er signal. All these phenomena likely play a role in CaSR-mediated
signalling [156,157]. Such models can facilitate interpretation of exper-
imental data, obtained for instance with FRET measurements of
G-protein activation, and support molecular understanding of the
altered behaviour of wild-type vs. mutated cooperative proteins
[23,144,158–160]. Several studies on GPCRs concluded that the
Monod–Wyman–Changeux (MWC) model of cooperative proteins
applies to membrane receptors, e.g. GPCRs [155,161–163]. The
cooperativity between subunits of the CaSR suggests that the MWC
model would be suitable to describe the CaSR.
3.2. Ligand biased signalling
The CaSR exhibits “ligand biased signalling” or “biased agonism”, a
phenomenon common to GPCRs [164], indicating that distinct ligands
or modulators bind preferentially to a speciﬁc state of the GPCR and
stabilise it. Thereby, ligands induce a bias in signalling towards a spe-
ciﬁc pathway at the expense of others. By investigating the inﬂuence
of several modulators on CaSR-associated signalling pathways, it has
been shown that the allosteric modulators cinacalcet, NPS-R568 and
the inhibitor NPS-2143 induce a preference towards intracellular
Ca2+ mobilisation rather than the phosphorylation of ERK1/2 as a
response of the activated receptor (Fig. 3) [145]. The evidence for bi-
ased signalling of the CaSR through different orthosteric agonists such
as divalent cations, polyamines and aminoglycosides, is increasing.
For example, Thomsen et al. showed that barium (Ba2+) biases
towards Gαi/o signalling in comparison to its potency to activate
Gαq/11 signalling. Further, the authors describe a general trend of
polyamines and aminoglycosides to inﬂuence CaSR signalling to-
wards ERK1/2 phosphorylation compared to Gαq/11 signalling [165].
In addition, the same authors demonstrated a biasing effect of stron-
tium on the potency of calcitonin secretion in comparison to calcium
stimulation in cells endogenously expressing the CaSR [166]. Not only
small molecule ligands, but also mutations of the CaSR gene can
induce biasing effects on the signal transduction [144], furtherindicating that the stabilisation of altered receptor conformations is
of key importance in the phenomenon of ligand biased signalling.
An extreme example of biased signalling by the CaSR has been
found in human oesophageal epithelial cells by Mulder et al. where,
the major basic protein (MBP) and its mimetic polyarginine induced
ﬁbroblast growth factor 9 (FGF9) secretion in a CaSR-dependent
manner while calcium alone had no effect [167]. The MWC model
allows for a molecular explanation of CaSR ligand-biased signalling.
A changed pattern of information ﬂow through a signalling network
is one of the deﬁning features of cancer; as an outcome the balance be-
tween apoptosis, differentiation and proliferation is disturbed. Alter-
ations in ligand-biased signalling because of mutations in GPCRs could
be one of the associated mechanisms. In addition, ligand biased signal-
ling could be used in chemotherapy to enhance the therapeutic effect
of drugs, enabling lower dosage and thus reducing side-effects. Indeed,
calcium can enhance sensitivity of colon cancer cell lines to cytotoxic
drugs [168]. Development of biased CaSR ligands that are more selective
for speciﬁc signalling pathways could widen the ﬁeld of utilisation of
calcimimetics and calcilytics [145]. These examples illustrate the impor-
tance of quantitative approaches to GPCRs. Moreover, mathematical
models of proteins can be a useful tool for drug design together with
protein structural modelling and the analysis of mutated receptors.
4. The CaSR as a potential cancer drug target
The role of CaSR agonists and antagonists for tumour prevention
or progression needs deeper understanding of the CaSR-mediated
signalling mechanisms. However, at present data on the potential
beneﬁt of cinacalcet, the only FDA-approved calcimimetic, for cancer
treatment are missing, except for parathyroid neoplasia.
As described above, treatment with cinacalcet was shown to reverse
parathyroid gland hyperplasia in a rodent model of chronic kidney dis-
ease [46]. Furthermore, cinacalcetwas effective in amurinemodel of pri-
mary hyperparathyroidism, which exhibited reduced CaSR expression in
parathyroid glands [169]. These improvements may be, in part, due to
calcimimetics promoting CaSR expression, as these disorders are
characterised by decreased CaSR expression. In nephrectomised rats,
for example, the calcimimetic NPS R-568 reversed reductions in CaSR
mRNA and protein expression caused by a high-phosphorous diet [47],
while the calcimimetic AMG 641 up-regulated CaSR and vitamin D re-
ceptor mRNA expression in uremic rats [48].
In addition, the CaSR seems to have a role in chemotherapy. Recent
studies have shown that CaSR signalling regulates the expression of
thymidylate synthase and survivin and intensiﬁes the effect of
5-ﬂuorouracil, one of the drugs of choice in colon cancer chemotherapy
[170,171]. Furthermore, in breast cancer, knocking down the tumour
suppressor gene BRAC1 leads to a downregulation of CaSR expression
and, consequently, to upregulation of survivin which reduced sensitivi-
ty to paclitaxel, a mitotic inhibitor used in chemotherapy [172].
Targeting the CaSR could therefore be important, not only for ﬁnd-
ing new therapeutic avenues to prevent/delay malignant transforma-
tion, but also to improve the efﬁciency of current treatments.
However, there are a number of important considerations that must
be taken into account:
1) The CaSR is widely expressed in many different cell types and tis-
sues throughout the body, therefore it may be important to devel-
op drugs and delivery forms that only reach the CaSR in a
tissue-speciﬁc way. This is an important consideration, as
off-target effects of potential CaSR-based therapies could be detri-
mental to patient health. Currently, the class of drugs used for
CaSR-based therapy, the phenylalkyamines, are themselves par-
tially selective for the parathyroid CaSR, over the CaSR expressed
in the thyroid C cells [173]. Therefore, selective targeting of the
CaSR in other organs, such as the breast, colon and prostate, is
important.
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Fig. 3. Physiological ligand biased signalling of the calcium sensing receptor (CaSR). The receptor conformation is dependent on the amount and type of ligands bound. Different
effector molecules bind preferentially to the different receptor states. This results in differential activation of the downstream signalling pathways. Arrow thickness correlates
with the direction of the bias signaling. Adapted from [181].
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onist of the CaSR, it is now becoming apparent that a number of
different molecules — including polyamines [174], L-amino acids
[175,176] and γ-glutamyl peptides [177] — are in fact primary
ligands in some physiological settings. These changes in primary
ligands are important, as the different ligands lead to preferential
stimulation of diverse signalling pathways, through ‘ligand-biased
signalling’. Consequently, identiﬁcation and targeting of different
CaSR ligands for speciﬁc tissues may also be an important part of
the drug development process.
3) Finally, the CaSR is a pleiotropic GPCR and readily couples to at least
three functionally diverse groups of heterotrimeric G proteins.
Furthermore, as mentioned previously, the CaSR is also reported to
switch G protein coupling from Gαi/0 to Gαs in certain pathophysio-
logical situations, including breast cancer [34]. Therefore, potential
novel therapies will most likely need to target speciﬁc G protein
usage.
These above considerations underline the multitude and complex-
ity of CaSR-mediated signalling and highlight the potential difﬁculties
in developing novel chemotherapeutics targeting the CaSR. A greater
understanding of these biological networks and the molecular inter-
actions that take place, aided by a systems biology approach, may
be essential in helping to address these issues.
5. Conclusions
Epidemiological and experimental evidence suggests that the
CaSR might play a role in tumour progression, however unequivocal
evidence for a direct link between the CaSR and tumourigenesis is
still lacking. CaSR seems to play a yin and yang role in cancer/cell
physiology because it transduces both anti- and pro-proliferativesignals, and inhibits or facilitates cell migration. The methodology of
systems biology is an excellent tool to help understand these complex
signalling networks. Using the ligand-biased signalling properties of
the CaSR could be instrumental in designing speciﬁc therapeutics in
different pathophysiological conditions.
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